AngioDynamics Q4 2024 Adj EPS $(0.05) Beats $(0.16) Estimate, Sales $71.122M Beat $70.891M Estimate
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics reported its Q4 2024 results, with an adjusted EPS of $(0.05), beating the estimate of $(0.16). Sales were $71.122 million, surpassing the $70.891 million estimate.
July 16, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AngioDynamics reported better-than-expected Q4 2024 results, with an adjusted EPS of $(0.05) beating the $(0.16) estimate and sales of $71.122 million surpassing the $70.891 million estimate.
The better-than-expected earnings and sales figures are likely to positively impact AngioDynamics' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100